Susan M. O’Brien, MD of University of California Irvine, gives an overview of Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia at the 58th ASH Annual Meeting in San Diego, CA.
Five-Year Experience with Single-Agent Ibrutinib
